BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31381135)

  • 1. The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer.
    Larsson P; Syed Khaja AS; Semenas J; Wang T; Sarwar M; Dizeyi N; Simoulis A; Hedblom A; Wai SN; Ødum N; Persson JL
    Int J Cancer; 2020 Mar; 146(6):1686-1699. PubMed ID: 31381135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FcγRIIIa receptor interacts with androgen receptor and PIP5K1α to promote growth and metastasis of prostate cancer.
    Larsson PF; Karlsson R; Sarwar M; Miftakhova R; Wang T; Syed Khaja AS; Semenas J; Chen S; Hedblom A; Ali A; Ekström-Holka K; Simoulis A; Kumar A; Wingren AG; Robinson B; Nyunt Wai S; Mongan NP; Heery DM; Öhlund D; Grundström T; Ødum N; Persson JL
    Mol Oncol; 2022 Jul; 16(13):2496-2517. PubMed ID: 34932854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted inhibition of ERα signaling and PIP5K1α/Akt pathways in castration-resistant prostate cancer.
    Semenas J; Wang T; Sajid Syed Khaja A; Firoj Mahmud A; Simoulis A; Grundström T; Fällman M; Persson JL
    Mol Oncol; 2021 Apr; 15(4):968-986. PubMed ID: 33275817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.
    Mandel A; Larsson P; Sarwar M; Semenas J; Syed Khaja AS; Persson JL
    Mol Med; 2018 Jun; 24(1):34. PubMed ID: 30134822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.
    Sarwar M; Syed Khaja AS; Aleskandarany M; Karlsson R; Althobiti M; Ødum N; Mongan NP; Dizeyi N; Johnson H; Green AR; Ellis IO; Rakha EA; Persson JL
    Oncogene; 2019 Jan; 38(3):375-389. PubMed ID: 30104711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.
    Sarwar M; Semenas J; Miftakhova R; Simoulis A; Robinson B; Gjörloff Wingren A; Mongan NP; Heery DM; Johnsson H; Abrahamsson PA; Dizeyi N; Luo J; Persson JL
    Oncotarget; 2016 Sep; 7(39):63065-63081. PubMed ID: 27588408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.
    Semenas J; Hedblom A; Miftakhova RR; Sarwar M; Larsson R; Shcherbina L; Johansson ME; Härkönen P; Sterner O; Persson JL
    Proc Natl Acad Sci U S A; 2014 Sep; 111(35):E3689-98. PubMed ID: 25071204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor promotes gastric cancer cell migration and invasion via AKT-phosphorylation dependent upregulation of matrix metalloproteinase 9.
    Zhang BG; Du T; Zang MD; Chang Q; Fan ZY; Li JF; Yu BQ; Su LP; Li C; Yan C; Gu QL; Zhu ZG; Yan M; Liu B
    Oncotarget; 2014 Nov; 5(21):10584-95. PubMed ID: 25301736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
    Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
    Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.
    Wegiel B; Bjartell A; Tuomela J; Dizeyi N; Tinzl M; Helczynski L; Nilsson E; Otterbein LE; Härkönen P; Persson JL
    J Natl Cancer Inst; 2008 Jul; 100(14):1022-36. PubMed ID: 18612129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.
    Hu S; Li L; Yeh S; Cui Y; Li X; Chang HC; Jin J; Chang C
    Mol Oncol; 2015 Jan; 9(1):44-57. PubMed ID: 25135278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
    Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIP5K1α is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer.
    Wang T; Sarwar M; Whitchurch JB; Collins HM; Green T; Semenas J; Ali A; Roberts CJ; Morris RD; Hubert M; Chen S; El-Schich Z; Wingren AG; Grundström T; Lundmark R; Mongan NP; Gunhaga L; Heery DM; Persson JL
    Front Cell Dev Biol; 2022; 10():798590. PubMed ID: 35386201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
    Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor and invasion in prostate cancer.
    Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
    Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
    Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
    IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone Receptor Expression in the Benign Prostatic Hyperplasia and Prostate Cancer Tissues, Relation with Transcription, Growth Factors, Hormone Reception and Components of the AKT/mTOR Signaling Pathway.
    Spirina LV; Kovaleva IV; Usynin EA; Goorbunov AK; Kondakova IV
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):423-429. PubMed ID: 32102520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.